Guardant Health announced the launch of its "Shield Across America" mobile screening tour, a coast‑to‑coast initiative that will bring the company’s FDA‑approved colorectal cancer blood test, Shield, to more than 100 U.S. communities, including stops in Las Vegas, Hartford, Atlanta and other rural locations.
The tour, timed to coincide with National Colorectal Cancer Awareness Month, focuses on areas with high screening barriers and mortality rates. By deploying mobile lab vans to local events, senior centers, and sporting venues, Guardant aims to increase screening uptake, accelerate early detection, and drive future revenue growth in its flagship screening business.
Shield is the first blood test approved by the FDA for primary colorectal cancer screening and the first to receive Medicare coverage. The test has a proven adherence rate of 93%, a figure that reflects strong patient acceptance and the convenience of a blood draw versus stool or colonoscopy procedures.
Guardant’s screening revenue grew to $35.1 million in Q4 2025 from approximately 38,000 tests and reached $79.7 million for the full 2025 year on about 87,000 tests. Management projects screening revenue of $162‑$174 million for 2026, driven in part by the mobile tour’s expanded reach.
Co‑CEO AmirAli Talasaz said the tour "seeks to address a fundamental challenge in colorectal cancer screening in our country: access," underscoring the company’s commitment to reducing disparities. He added that Shield is "the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver for Guardant."
The mobile tour represents a strategic operational milestone that is expected to capture a larger share of the CRC screening market, support Guardant’s revenue guidance, and reinforce its leadership position in liquid biopsy diagnostics.
The announcement was made on March 4 2026, and the tour is scheduled to begin immediately, marking a new chapter in Guardant’s expansion of Shield’s reach across the United States.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.